Fig. 2From: Comorbidity burden and survival in patients with idiopathic pulmonary fibrosis: the EMPIRE registry studyOverall survival in patients with IPF by comorbidities at enrolment according to antifibrotic therapy. Comorbidities for (a) those receiving antifibrotic therapy (n = 2257) and (b) those not receiving antifibrotic therapy (n = 1323). Antifibrotic therapies were nintedanib or pirfenidone. IPF, idiopathic pulmonary fibrosisBack to article page